No Data
Express News | AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Express News | AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
Press Release: AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech and Erasmus MC Announce Progress on Phase 2 Trial for Ampligen and Imfinzi in Late-Stage Pancreatic Cancer
AIM ImmunoTech Releases Virtual Investor "What This Means Segment"
what do you think can go up to
Karoline Mikkelsen : next trad position need to be delete!!!
Viking Trader : why you so quiet Aim